Compare AX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | ABCL |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | 2004 | 2020 |
| Metric | AX | ABCL |
|---|---|---|
| Price | $91.87 | $11.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $117.71 | $17.17 |
| AVG Volume (30 Days) | 332.7K | ★ 3.8M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.13 | 10.91 |
| EPS | ★ 2.25 | N/A |
| Revenue | ★ $81,254,000.00 | $75,128,000.00 |
| Revenue This Year | $11.96 | N/A |
| Revenue Next Year | $9.49 | $7.12 |
| P/E Ratio | $42.03 | ★ N/A |
| Revenue Growth | 23.51 | ★ 160.56 |
| 52 Week Low | $74.89 | $2.75 |
| 52 Week High | $105.74 | $14.98 |
| Indicator | AX | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 49.85 |
| Support Level | $94.35 | $11.78 |
| Resistance Level | $100.94 | $12.88 |
| Average True Range (ATR) | 2.34 | 0.90 |
| MACD | 0.60 | -0.06 |
| Stochastic Oscillator | 68.62 | 43.72 |
Axos Financial Inc is a technology-driven, diversified financial services company. Its client-centric, technology-enabled services model provides secure and scalable banking, clearing and custody, and investment advisory solutions to retail and business customers. The Bank provides consumer and commercial banking products and services through its digital online and mobile banking platforms, low-cost distribution channels and affinity partners. It offers deposit and lending products to customers nationwide including consumer and business checking, savings, etc. Its segments are Banking Business Segment and the Securities Business Segment. Majority of income comes from Banking Business Segment- It distribute its loan products through its retail, correspondent and wholesale channels.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.